Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma

NCT01175109 is registered in ClinicalTrials.gov with Deric M Park MD as lead sponsor.

NCT NCT01175109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01175109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase I Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
Lead sponsor
Deric M Park MD
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2011
Completion date
December 31, 2013
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

chordoma